Pharmacotherapy for Panic Disorder and Agoraphobia

Oxford Handbook of Anxiety and Related Disorders

Volumn , Issue , 2008, Pages

  Pollack, Mark H ^a,b   Simon, Naomi M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Agoraphobia; Anxiety; Cognitive behavioral therapy; Panic; Pharmacotherapy

Indexed keywords

EID: 72849119106     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/oxfordhb/9780195307030.013.0022     Document Type: Chapter

References (131)

1. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
2. American Psychiatric Association. (1998). Practice guideline for the treatment of patients with panic disorder. Work Group on Panic Disorder. American Journal of Psychiatry, 155(Suppl. 5), 1-34.
3. Asnis, G. M., Hameedi, F. A., Goddard, A. W., Potkin, S. G., Black, D., Jameel, M., et al. (2001). Fluvoxamine in the treatment of panic disorder: A multicenter, double-blind, placebo-controlled study in outpatients. Psychiatry Research, 103, 1-14.
4. Bakish, D., Hooper, C. L., Filteau, M. J., Charbonneau, Y., Fraser, G., West, D. L., et al. (1996). A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacology Bulletin, 32, 135-141.
5. Bakish, D., Saxena, B. M., Bowen, R., & D'Souza, J. (1993). Reversible monoamine oxidase-A inhibitors in panic disorder. Clinical Neuropharmacology, 16(Suppl. 2), S77-82.
6. Bakker, A., van Balkom, A. J., & Spinhoven, P. (2002). SSRIs vs. TCAs in the treatment of panic disorder: A metaanalysis. Acta Psychiatrica Scandinavica, 106, 163-167.
7. Bakker, A., van Balkom, A. J., & Stein, D. J. (2005). Evidence-based pharmacotherapy of panic disorder. International Journal of Neuropsychopharmacology, 8, 473-482.
8. Bakker, A., van Dyck, R., Spinhoven, P., & van Balkom, A. J. (1999). Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. Journal of Clinical Psychiatry, 60, 831-838.
9. Ball, S. G., Otto, M. W., Pollack, M. H., & Rosenbaum, J. F. (1994). Predicting prospective episodes of depression in patients with panic disorder: A longitudinal study. Journal of Consulting and Clinical Psychology, 62, 359-365.
10. Ballenger, J. C., Davidson, J. R., Lecrubier, Y., Nutt, D. J., Baldwin, D. S., den Boer, J. A., et al. (1998). Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. Journal of Clinical Psy-chiatry, 59(Suppl. 8), 47-54.
11. Ballenger, J. C., Wheadon, D. E., Steiner, M., Bushnell, W., & Gergel, I. P. (1998). Double-blind, fixed-dose, placebocontrolled study of paroxetine in the treatment of panic disorder. American Journal of Psychiatry, 155, 36-42.
12. Bertani, A., Perna, G., Migliarese, G., Di Pasquale, D., Cucchi, M., Caldirola, D., et al. (2004). Comparison of the treatment with paroxetine and reboxetine in panic disorder: A randomized, single-blind study. Pharmacopsychiatry, 37, 206-210.
13. Bhagwagar, Z., Wylezinska, M., Taylor, M., Jezzard, P., Matthews, P. M., & Cowen, P. J. (2004). Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. American Journal of Psychiatry, 161, 368-370.
14. Black, D. W., Wesner, R., Bowers, W., & Gabel, J. (1993). A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Archives of General Psychiatry, 50, 44-50.
15. Bouvard, M., Mollard, E., Guerin, J., & Cottraux, J. (1997). Study and course of the psychological profile in 77 patients expressing panic disorder with agoraphobia after cognitive behaviour therapy with or without buspirone. Psychotherapy and Psychosomatics, 66, 27-32.
16. Bruce, S. E., Vasile, R. G., Goisman, R. M., Salzman, C., Spencer, M., Machan, J. T., et al. (2003). Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? American Journal of Psychiatry, 160, 1432-1438.
17. Charney, D. S., Heninger, G. R., & Breier, A. (1984). Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Archives of General Psychiatry, 41, 751-763.
18. Charney, D. S., & Woods, S. W. (1989). Benzodiazepine treatment of panic disorder: A comparison of alprazolam and lorazepam. Journal of Clinical Psychiatry, 50, 418-423.
19. Coplan, J. D., & Lydiard, R. B. (1998). Brain circuits in panic disorder. Biological Psychiatry, 44, 1264-1276.
20. Cowley, D. S., Ha, E. H., & Roy-Byrne, P. P. (1997). Determinants of pharmacologic treatment failure in panic disorder. Journal of Clinical Psychiatry, 58, 555-561; quiz 562-553.
21. Cramer, V., Torgersen, S., & Kringlen, E. (2005). Quality of life and anxiety disorders: A population study. Journal of Nervous and Mental Disease, 193, 196-202.
22. Crippa, J. A., & Zuardi, A. W. (2006). Duloxetine in the treatment of panic disorder. International Journal of Neuropsycho-pharmacology, 9, 633-634.
23. Dannon, P. N., Iancu, I., Cohen, A., Lowengrub, K., Grunhaus, L., & Kotler, M. (2004). Three year naturalistic outcome study of panic disorder patients treated with paroxetine. BMC Psychiatry, 4, 16.
24. Davidson, J. R., Beitman, B., Greist, J. H., Maddock, R. J., Lewis, C. P., Sheridan, A. Q., et al. (1994). Adinazolam sustained-release treatment of panic disorder: A double-blind study. Journal of Clinical Psychopharmacology, 14, 255-263.
25. De Beurs, E., van Balkom, A. J., Lange, A., Koele, P., & van Dyck, R. (1995). Treatment of panic disorder with agoraphobia: Comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. American Journal of Psychiatry, 152, 683-691.
26. Den Boer, J. A., & Westenberg, H. G. (1988). Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder: A double-blind comparative study with fluvoxamine and maprotiline. International Clinical Psychopharmacology, 3, 59-74.
27. Den Boer, J. A., Westenberg, H. G., Kamerbeek, W. D., Verhoeven, W. M., & Kahn, R. S. (1987). Effect of serotonin uptake inhibitors in anxiety disorders: A double-blind comparison of clomipramine and fluvoxamine. International Clinical Psychopharmacology, 2, 21-32.
28. Dunner, D. L., Ishiki, D., Avery, D. H., Wilson, L. G., & Hyde, T. S. (1986). Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: A controlled study. Journal of Clinical Psychiatry, 47, 458-460.
29. Eaton, W. W., Kessler, R. C., Wittchen, H. U., & Magee, W. J. (1994). Panic and panic disorder in the United States. American Journal of Psychiatry, 151, 413-420.
30. Ettigi, P., Meyerhoff, A. S., Chirban, J. T., Jacobs, R. J., & Wilson, R. R. (1997). The quality of life and employment in panic disorder. Journal of Nervous and Mental Disease, 18, 368-372.
31. Fava, M. (2006). Prospective studies of adverse events related to antidepressant discontinuation. Journal of Clinical Psychiatry, 67(Suppl. 4), 14-21.
32. Fava, M., Judge, R., Hoog, S. L., Nilsson, M. E., & Koke, S. C. (2000). Fluoxetine versus sertraline and paroxetine in major depressive disorder: Changes in weight with long-term treatment. Journal of Clinical Psychiatry, 61, 863-867.
33. Furukawa, T. A., Watanabe, N., & Churchill, R. (2006). Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: Systematic review. British Journal of Psychiatry, 188, 305-312.
34. Gastfriend, D. R., & Rosenbaum, J. F. (1989). Adjunctive buspirone in benzodiazepine treatment of four patients with panic disorder. American Journal of Psychiatry, 146, 914-916.
35. Gaudreault, P., Guay, J., Thivierge, R. L., & Verdy, I. (1991). Benzodiazepine poisoning: Clinical and pharmacological considerations and treatment. Drug Safety, 6, 247-265.
36. Goddard, A. W., Brouette, T., Almai, A., Jetty, P., Woods, S. W., & Charney, D. (2001). Early coadministration of clonazepam with sertraline for panic disorder. Archives of General Psychiatry, 58, 681-686.
37. Goddard, A. W., Mason, G. F., Almai, A., Rothman, D. L., Behar, K. L., Petroff, O. A., et al. (2001). Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. Archives of General Psychiatry, 58, 556-561.
38. Goodwin, R. D., & Roy-Byrne, P. (2006). Panic and suicidal ideation and suicide attempts: Results from the National Comorbidity Survey. Depression and Anxiety, 23, 124-132.
39. Gorman, J. M., Kent, J. M., Sullivan, G. M., & Coplan, J. D. (2000). Neuroanatomical hypothesis of panic disorder, revised. American Journal of Psychiatry, 157, 493-505.
40. Greenblatt, D. J., Shader, R. I., & Abernethy, D. R. (1983). Drug therapy: Current status of benzodiazepines. New England Journal of Medicine, 309, 354-358.
41. Hirschmann, S., Dannon, P. N., Iancu, I., Dolberg, O. T., Zohar, J., & Grunhaus, L. (2000). Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology, 20, 556-559.
42. Hoehn-Saric, R., McLeod, D. R., & Hipsley, P. A. (1993). Effect of fluvoxamine on panic disorder. Journal of Clinical Psycho-pharmacology, 13, 321-326.
43. Hollifield, M., Thompson, P. M., Ruiz, J. E., & Uhlenhuth, E. H. (2005). Potential effectiveness and safety of olanzapine in refractory panic disorder. Depression and Anxiety, 21, 33-40.
44. Kan, C. C., Hilberink, S. R., & Breteler, M. H. (2004). Determination of the main risk factors for benzodiazepine dependence using a multivariate and multidimensional approach. Comprehensive Psychiatry, 45, 88-94.
45. Katon, W. (1996). Panic disorder: Relationship to high medical utilization, unexplained physical symptoms, and medical costs. Journal of Clinical Psychiatry, 57(Suppl. 10), 11-18; discussion 19-22.
46. Katschnig, H., & Amering, M. (1998). The long-term course of panic disorder and its predictors. Journal of Clinical Psycho-pharmacology, 18(6 Suppl. 2), 6S-11S.
47. Keller, M. B., & Baker, L. A. (1992). The clinical course of panic disorder and depression. Journal of Clinical Psychiatry, 53(Suppl.), 5-8.
48. Keller, M. B., Yonkers, K. A., Warshaw, M. G., Pratt, L. A., Gollan, J. K., Massion, A. O., et al. (1994). Remission and relapse in subjects with panic disorder and panic with agoraphobia: A prospective short-interval naturalistic followup. Journal of Nervous and Mental Disease, 182, 290-296.
49. Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62, 593-602.
50. Kessler, R. C., McGonagle, K. A., Zhao, S., Nelson, C. B., Hughes, M., Eshleman, S., et al. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry, 51, 8-19.
51. Klein, D. F., & Fink, M. (1962). Psychiatric reaction patterns to imipramine. American Journal of Psychiatry, 119, 432-438.
52. Lecrubier, Y., Bakker, A., Dunbar, G., & Judge, R. (1997). A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatrica Scandinavica, 95, 145-152.
53. Lecrubier, Y., & Judge, R. (1997). Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatrica Scandinavica, 95, 153-160.
54. Lepola, U. M., Wade, A. G., Leinonen, E. V., Koponen, H. J., Frazer, J., Sjodin, I., et al. (1998). A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. Journal of Clinical Psychiatry, 59, 528-534.
55. Lippman, S. B., & Nash, K. (1990). Monoamine oxidase inhibitor update: Potential adverse food and drug interactions. Drug Safety, 5, 195-204.
56. Livingston, M. G., & Livingston, H. M. (1996). Monoamine oxidase inhibitors: An update on drug interactions. Drug Safety, 14, 219-227.
57. Loerch, B., Graf-Morgenstern, M., Hautzinger, M., Schlegel, S., Hain, C., Sandmann, J., et al. (1999). Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia. British Journal of Psychiatry, 174, 205-212.
58. Londborg, P. D., Wolkow, R., Smith, W. T., DuBoff, E., England, D., Ferguson, J., et al. (1998). Sertraline in the treatment of panic disorder: A multisite, double-blind, placebo-controlled, fixed-dose investigation. British Journal of Psychiatry, 173, 54-60.
59. Lum, M., Fontaine, R., & Elie, R. (1990). Divalproex sodium's antipanic effect in panic disorder: A placebocontrolled study. Biological Psychiatry, 27(Suppl. 1), 164A-165A.
60. Lydiard, R. B., Steiner, M., Burnham, D., & Gergel, I. (1998). Efficacy studies of paroxetine in panic disorder. Psychopha-macology Bulletin, 34, 175-182.
61. Markowitz, J. S., Weissman, M. M., Ouellette, R., Lish, J. D., & Klerman, G. L. (1989). Quality of life in panic disorder. Archives of General Psychiatry, 46, 984-992.
62. Maron, E., Kuikka, J. T., Shlik, J., Vasar, V., Vanninen, E., & Tiihonen, J. (2004). Reduced brain serotonin transporter binding in patients with panic disorder. Psychiatry Research, 132, 173-181.
63. Mavissakalian, M. R., & Perel, J. M. (2002). Duration of imipramine therapy and relapse in panic disorder with agoraphobia. Journal of Clinical Psychopharmacology, 22, 294-299.
64. Michelson, D., Allgulander, C., Dantendorfer, K., Knezevic, A., Maierhofer, D., Micev, V., et al. (2001). Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: Randomised, placebo-controlled trial. British Journal of Psychiatry, 179, 514-518.
65. Michelson, D., Lydiard, R. B., Pollack, M. H., Tamura, R. N., Hoog, S. L., Tepner, R., et al. (1998). Outcome assessment and clinical improvement in panic disorder: Evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. American Journal of Psychiatry, 155, 1570-1577.
66. Michelson, D., Pollack, M., Lydiard, R. B., Tamura, R., Tepner, R., & Tollefson, G. (1999). Continuing treatment of panic disorder after acute response: Randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. British Journal of Psychiatry, 174, 213-218.
67. Modell, J. G., Katholi, C. R., Modell, J. D., & DePalma, R. L. (1997). Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clinical Pharmacology and Therapeutics, 61, 476-487.
68. Munjack, D. J., Crocker, B., Cabe, D., Brown, R., Usigli, R., Zu-lueta, A., et al. (1989). Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. Journal of Clinical Psychopharmacology, 9, 22-27.
69. Nagy, L. M., Krystal, J. H., Woods, S. W., & Charney, D. S. (1989). Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder: 2.5 year naturalistic follow-up study. Archives of General Psychiatry, 46, 993-999.
70. Nesse, R. M., Cameron, O. G., Curtis, G. C., McCann, D. S., & Huber-Smith, M. J. (1984). Adrenergic function in patients with panic anxiety. Archives of General Psychiatry, 41, 771-776.
71. Noyes, R., Jr., Burrows, G. D., Reich, J. H., Judd, F. K., Garvey, M. J., Norman, T. R., et al. (1996). Diazepam versus alprazolam for the treatment of panic disorder. Journal of Clinical Psychiatry, 57, 349-355.
72. Noyes, R., Jr., & Perry, P. (1990). Maintenance treatment with antidepressants in panic disorder. Journal of Clinical Psychiatry, 51(Suppl. A), 24-30.
73. Nutt, D. J. (1998). Antidepressants in panic disorder: Clinical and preclinical mechanisms. Journal of Clinical Psychiatry, 59(Suppl. 8), 24-28; discussion 29.
74. Oehrberg, S., Christiansen, P. E., Behnke, K., Borup, A. L., Severin, B., Soegaard, J., et al. (1995). Paroxetine in the treatment of panic disorder: A randomised, double-blind, placebo-controlled study. British Journal of Psychiatry, 167, 374-379.
75. Otto, M. W., Pollack, M. H., Sachs, G. S., Reiter, S. R., Meltzer-Brody, S., & Rosenbaum, J. F. (1993). Discontinuation of benzodiazepine treatment: Efficacy of cognitive-behavioral therapy for patients with panic disorder. American Journal of Psychiatry, 150, 1485-1490.
76. Otto, M. W., Tuby, K. S., Gould, R. A., McLean, R. Y., & Pollack, M. H. (2001). An effectsize analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. American Journal of Psychiatry, 158, 1989-1992.
77. Palatnik, A., Frolov, K., Fux, M., & Benjamin, J. (2001). Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. Journal of Clinical Psycho-pharmacology, 21, 335-339.
78. Pande, A. C., Pollack, M. H., Crockatt, J., Greiner, M., Chouinard, G., Lydiard, R. B., et al. (2000). Placebo-controlled study of gabapentin treatment of panic disorder. Journal of Clinical Psychopharmacology, 20, 467-471.
79. Pecknold, J. C., Swinson, R. P., Kuch, K., & Lewis, C. P. (1988). Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial. III. Discontinuation effects. Archives of General Psychiatry, 45, 429-436.
80. Pohl, R. B., Wolkow, R. M., & Clary, C. M. (1998). Sertraline in the treatment of panic disorder: A double-blind multicenter trial. American Journal of Psychiatry, 155, 1189-1195.
81. Pollack, M. H. (2005). The pharmacotherapy of panic disorder. Journal of Clinical Psychiatry, 66(Suppl. 4), 23-27.
82. Pollack, M. H., Allgulander, C., Bandelow, B., Cassano, G. B., Greist, J. H., Hollander, E., et al. (2003). WCA recommendations for the long-term treatment of panic disorder. CNS Spectrums, 8(8 Suppl. 1), 17-30.
83. Pollack, M. H., Lepola, U., Koponen, H., Simon, N. M., Worthington, J. J., Emilien, G., et al. (2007). A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depression and Anxiety, 24(1), 1-14.
84. Pollack, M., Mangano, R., Entsuah, R., Tzanis, E., & Simon, N. M. (2007). A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology, 194(2), 233-242.
85. Pollack, M. H., Otto, M. W., Rosenbaum, J. F., Sachs, G. S., O'Neil, C., Asher, R., et al. (1990). Longitudinal course of panic disorder: Findings from the Massachusetts General Hospital Naturalistic Study. Journal of Clinical Psychiatry, 51(Suppl. A), 12-16.
86. Pollack, M. H., Otto, M. W., Sabatino, S., Majcher, D., Worthington, J. J., McArdle, E. T., et al. (1996). Relationship of childhood anxiety to adult panic disorder: Correlates and influence on course. American Journal of Psychiatry, 153, 376-381.
87. Pollack, M. H., Otto, M. W., Tesar, G. E., Cohen, L. S., Meltzer-Brody, S., & Rosenbaum, J. F. (1993). Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. Journal of Clinical Psychopharmacology, 13, 257-263.
88. Pollack, M. H., Otto, M. W., Worthington, J. J., Manfro, G. G., & Wolkow, R. (1998). Sertraline in the treatment of panic disorder: A flexible-dose multicenter trial. Archives of General Psychiatry, 55, 1010-1016.
89. Pollack, M. H., Simon, N. M., Worthington, J. J., Doyle, A. L., Peters, P., Toshkov, F., et al. (2003). Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. Journal of Psychopharmacol-ogy, 17, 276-282.
90. Pollack, M. H., & Smoller, J. W. (1995). The longitudinal course and outcome of panic disorder. Psychiatric Clinics of North America, 18, 785-801.
91. Pollack, M. H., Worthington, J. J., III, Otto, M. W., Maki, K. M., Smoller, J. W., Manfro, G. G., et al. (1996). Venlafaxine for panic disorder: Results from a double-blind, placebo-controlled study. Psychopharmacology Bulletin, 32, 667-670.
92. Primeau, F., & Fontaine, R. (1988). GABAergic agents and panic disorder. Biological Psychiatry, 24, 942-943.
93. Rapaport, M. H., Wolkow, R., Rubin, A., Hackett, E., Pollack, M., & Ota, K. Y. (2001). Sertraline treatment of panic disorder: Results of a long-term study. Acta Psychiatrica Scandi-navica, 104, 289-298.
94. Redmond, D. E., Jr., & Huang, Y. H. (1979). Current concepts: II. New evidence for a locus coeruleusnorepinephrine connection with anxiety. Life Sciences, 25, 2149-2162.
95. Rickels, K., Pollack, M. H., Feltner, D. E., Lydiard, R. B., Zimbroff, D. L., Bielski, R. J., et al. (2005). Pregabalin for treatment of generalized anxiety disorder: A 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Archives of General Psychiatry, 62, 1022-1030.
96. Rickels, K., Schweizer, E., Weiss, S., & Zavodnick, S. (1993). Maintenance drug treatment for panic disorder: II. Shortand long-term outcome after drug taper. Archives of General Psychiatry, 50, 61-68.
97. Rosenbaum, J. F., Pollack, M. H., & Fredman, S. J. (1998). The pharmacotherapy of panic disorder. In J. F. Rosenbaum & M. H. Pollack (Eds.), Panic disorder and its treatment (pp. 153-180). New York: Marcel Dekker.
98. Roy-Byrne, P. P., & Cowley, D. S. (1994). Course and outcome in panic disorder: A review of recent follow-up studies. Anxi-ety, 1, 151-160.
99. Roy-Byrne, P. P., Craske, M. G., & Stein, M. B. (2006). Panic disorder. Lancet, 368, 1023-1032.
100. Roy-Byrne, P. P., Stein, M. B., Russo, J., Mercier, E., Thomas, R., McQuaid, J., et al. (1999). Panic disorder in the primary care setting: Comorbidity, disability, service utilization, and treatment. Journal of Clinical Psychiatry, 60, 492-499; quiz 500.
101. Roy-Byrne, P., Wingerson, D. K., Radant, A., Greenblatt, D. J., & Cowley, D. S. (1996). Reduced benzodiazepine sensitivity in patients with panic disorder: Comparison with patients with obsessive-compulsive disorder and normal subjects. American Journal of Psychiatry, 153, 1444-1449.
102. Rubin, H. C., Rapaport, M. H., Levine, B., Gladsjo, J. K., Rabin, A., Auerbach, M., et al. (2000). Quality of well being in panic disorder: The assessment of psychiatric and general disability. Journal of Affective Disorders, 57, 217-221.
103. Schweizer, E., Fox, I., Case, G., & Rickels, K. (1988). Lorazepam vs. alprazolam in the treatment of panic disorder. Psychopharmacology Bulletin, 24, 224-227.
104. Schweizer, E., Pohl, R., Balon, R., Fox, I., Rickels, K., & Yeragani, V. K. (1990). Lorazepam vs. alprazolam in the treatment of panic disorder. Pharmacopsychiatry, 23, 90-93.
105. Sharp, D. M., Power, K. G., Simpson, R. J., Swanson, V., & Anstee, J. A. (1997). Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care. British Journal of General Practice, 47, 150-155.
106. Shear, M. K., Rucci, P., Williams, J., Frank, E., Grochocinski, V., Vander Bilt, J., et al. (2001). Reliability and validity of the Panic Disorder Severity Scale: Replication and extension. Journal of Psychiatric Research, 35, 293-296.
107. Sheehan, D. V., Ballenger, J., & Jacobsen, G. (1980). Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Archives of General Psychiatry, 37, 51-59.
108. Sheehan, D. V., Burnham, D. B., Iyengar, M. K., & Perera, P. (2005). Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. Journal of Clinical Psychiatry, 66, 34-40.
109. Sheehan, D. V., Davidson, J., Manschreck, T., & Van Wyck Fleet, J. (1983). Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. Journal of Clinical Psychopharmacology, 3, 28-31.
110. Sheehan, D. V., Raj, A. B., Harnett-Sheehan, K., Soto, S., & Knapp, E. (1993). The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: A double-blind placebo-controlled study. Acta Psychiatrica Scandinavica, 88, 1-11.
111. Sheehan, D. V., Raj, A. B., Sheehan, K. H., & Soto, S. (1990). Is buspirone effective for panic disorder? Journal of Clinical Psychopharmacology, 10, 3-11.
112. Sheikh, J. I., Londborg, P., Clary, C. M., & Fayyad, R. (2000). The efficacy of sertraline in panic disorder: Combined results from two fixed-dose studies. International Clinical Psycho-pharmacology, 15, 335-342.
113. Simon, N. M., Emmanuel, N., Ballenger, J., Worthington, J. J., Kinrys, G., Korbly, N. B., et al. (2003). Bupropion sustained release for panic disorder. Psychopharmacology Bulletin, 37, 66-72.
114. Simon, N. M., Hoge, E. A., Fischmann, D., Worthington, J. J., Christian, K. M., Kinrys, G., et al. (2006). An open-label trial of risperidone augmentation for refractory anxiety disorders. Journal of Clinical Psychiatry, 67, 381-385.
115. Simpson, H. B., Schneier, F. R., Campeas, R. B., Marshall, R. D., Fallon, B. A., Davies, S., et al. (1998). Imipramine in the treatment of social phobia. Journal of Clinical Psychopharmacology, 18, 132-135.
116. Soumerai, S. B., Simoni-Wastila, L., Singer, C., Mah, C., Gao, X., Salzman, C., et al. (2003). Lack of relationship between long-term use of benzodiazepines and escalation to high dosages. Psychiatric Services, 54, 1006-1011.
117. Stahl, S. M., Gergel, I., & Li, D. (2003). Escitalopram in the treatment of panic disorder: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry, 64, 1322-1327.
118. Stein, D. J. (2005). The neurobiology of panic disorder: Toward an integrated model. CNS Spectrums, 9(Suppl. 12), 12-24.
119. Stein, D. J., Seedat, S., van der Linden, G. J., & Zungu-Dirwayi, N. (2000). Selective serotonin reuptake inhibitors in the treatment of posttraumatic stress disorder: A meta-analysis of randomized controlled trials. International Clinical Psycho-pharmacology, 15(Suppl. 2), S31-39.
120. Stewart, S. A. (2005). The effects of benzodiazepines on cognition. Journal of Clinical Psychiatry, 66(Suppl. 2), 9-13.
121. Tiller, J. W., Bouwer, C., & Behnke, K. (1999). Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. European Archives of Psychiatry and Clinical Neuroscience, 249(Suppl. 1), S7-10.
122. Uhde, T. W., Stein, M. B., & Post, R. M. (1988). Lack of efficacy of carbamazepine in the treatment of panic disorder. American Journal of Psychiatry, 145, 1104-1109.
123. Van Vliet, I. M., den Boer, J. A., Westenberg, H. G., & Slaap, B. R. (1996). A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. Journal of Clinical Psychopharmacology, 16, 299-306.
124. Van Vliet, I. M., Westenberg, H. G., & den Boer, J. A. (1993). MAO inhibitors in panic disorder: Clinical effects of treatment with brofaromine. A double blind placebo controlled study. Psychopharmacology (Berl), 112, 483-489.
125. Versiani, M., Cassano, G., Perugi, G., Benedetti, A., Mastalli, L., Nardi, A., et al. (2002). Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. Journal of Clinical Psychiatry, 63, 31-37.
126. Wade, A. G., Lepola, U., Koponen, H. J., Pedersen, V., & Pedersen, T. (1997). The effect of citalopram in panic disorder. British Journal of Psychiatry, 170, 549-553.
127. Warshaw, M. G., Massion, A. O., Shea, M. T., Allsworth, J., & Keller, M. B. (1997). Predictors of remission in patients with panic with and without agoraphobia: Prospective 5-year follow-up data. Journal of Nervous and Mental Disease, 185, 517-519.
128. Woodman, C. L., & Noyes, R., Jr. (1994). Panic disorder: Treatment with valproate. Journal of Clinical Psychiatry, 55, 134-136.
129. Worthington, J. J., III, Kinrys, G., Wygant, L. E., & Pollack, M. H. (2005). Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. International Clinical Psychopharmacology, 20, 9-11.
130. Yonkers, K. A., Zlotnick, C., Allsworth, J., Warshaw, M., Shea, T., & Keller, M. B. (1998). Is the course of panic disorder the same in women and men? American Journal of Psychiatry, 155, 596-602.
131. Zwanzger, P., & Rupprecht, R. (2005). Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. Journal of Psychiatry and Neu-roscience, 30, 167-175.